Literature DB >> 32369286

A Trial of Lopinavir-Ritonavir in Covid-19. Reply.

Bin Cao1, Dingyu Zhang2, Chen Wang3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32369286     DOI： 10.1056/NEJMc2008043

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

1.  Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.

Authors:  Zheng Zequn; W U Yujia; Q I A N Dingding; L I A N Jiangfang
Journal:  Eur J Pharmacol       Date:  2020-12-17       Impact factor: 4.432

2.  COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.

Authors:  Cirino Botta; Alessia Indrieri; Eugenio Garofalo; Flavia Biamonte; Andrea Bruni; Pino Pasqua; Francesco Cesario; Francesco Saverio Costanzo; Federico Longhini; Francesco Mendicino
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

Review 3.  Confronting the threat of SARS-CoV-2: Realities, challenges and therapeutic strategies (Review).

Authors:  Ruixue Wang; Xiaoshan Luo; Fang Liu; Shuhong Luo
Journal:  Exp Ther Med       Date:  2020-12-17       Impact factor: 2.751

4.  Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.

Authors:  Wei-Chung Chiou; Meng-Shiuan Hsu; Yun-Ti Chen; Jinn-Moon Yang; Yeou-Guang Tsay; Hsiu-Chen Huang; Cheng Huang
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

5.  Association between COVID-19 cases and international equity indices.

Authors:  Nick James; Max Menzies
Journal:  Physica D       Date:  2020-12-23       Impact factor: 2.300

6.  Chest Computed Tomography (CT) as a Predictor of Clinical Course in Coronavirus Disease.

Authors:  Bartosz Mruk; Jerzy Walecki; Andrzej Górecki; Agnieszka Kostkiewicz; Katarzyna Sklinda
Journal:  Med Sci Monit       Date:  2021-06-03

7.  The Course of Mild and Moderate COVID-19 Infections-The Unexpected Long-Lasting Challenge.

Authors:  Lu Xia; Jun Chen; Thomas Friedemann; Zongguo Yang; Yun Ling; Xuhui Liu; Shuihua Lu; Tao Li; Zhigang Song; Wei Huang; Yunfei Lu; Sven Schröder; Hongzhou Lu
Journal:  Open Forum Infect Dis       Date:  2020-07-23       Impact factor: 3.835

8.  Changes to the extreme and erratic behaviour of cryptocurrencies during COVID-19.

Authors:  Nick James; Max Menzies; Jennifer Chan
Journal:  Physica A       Date:  2020-11-25       Impact factor: 3.778

9.  Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.

Authors:  Jean Claude Alvarez; Pierre Moine; Benjamin Davido; Isabelle Etting; Djillali Annane; Islam Amine Larabi; Nicolas Simon
Journal:  Eur J Clin Pharmacol       Date:  2020-10-13       Impact factor: 2.953

10.  Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis.

Authors:  Xiaolin Zhang; Di Cao; Junnan Liu; Qi Zhang; Mingjun Liu
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.